Prostate cancer Board decisions

The Board denied an earlier effective date for the grant of service connection for prostate cancer, finding that July 11, 2016, is the proper effective date.

The Board remands the claim for service connection of prostate cancer and residuals, to include urinary frequency, due to a lack of medical evidence linking these conditions to the Veteran's military service.

The Board granted service connection for prostate cancer, to include as due to herbicide exposure, based on new and relevant evidence.

The Veteran was granted an effective date of December 12, 2023, for the 60 percent evaluation of prostate cancer status post robotic assisted radical retropubic with residual voiding dysfunction. The claims for earlier effective dates for a painful prostatectomy scar and sleep apnea with pleural plaques were denied.

The Board remands the claims for service connection for prostate cancer, NHL, hypothyroidism, DM II, and an acquired psychiatric disorder to correct a duty to assist error that occurred prior to the October 2024 rating decision.

The Board denied the Veteran's claim for special monthly compensation (SMC) based on aid and attendance, finding that he does not meet the criteria due to his service-connected disabilities.

The Veteran withdrew his appeal for service connection for erectile dysfunction, prostate cancer, hearing loss, tinnitus, diabetes mellitus, PTSD, sleep apnea, and vision loss.

The Board denied increased ratings for prostate cancer residuals, upper and trunk scars but granted a total disability rating based on individual unemployability due to service-connected disabilities.

The Board denied the Veteran's claim for an increased, compensable disability evaluation for his service-connected prostate cancer.

The Board remands the claims for an earlier effective date for prostate cancer, erectile dysfunction as secondary to prostate cancer, and special monthly compensation (SMC) based on the loss of use of a creative organ due to a pre-decisional duty to assist error.

The Board denied a higher rating for prostate cancer residuals and granted an effective date of January 26, 2021, for the grant of TDIU and DEA.

The Board remands the claims for service connection due to a duty to assist error that occurred prior to the respective rating decisions on appeal.

The Board granted service connection for prostate cancer and diabetes mellitus type 2 based on the Veteran's presumed exposure to herbicide agents during service.

The Board denied service connection for prostate cancer and diabetes, finding no evidence of a causal relationship between the conditions and active-duty service or toxic herbicide exposure.

The Board denied the claims for service connection for prostate cancer and diabetes mellitus, type II due to a lack of evidence supporting exposure to herbicide agents during service.

The Board remands the claims for service connection for prostate cancer and chronic lymphocytic lymphoma leukemia (CLL) to verify the Veteran's National Guard service dates and obtain medical opinions regarding a possible link between exposure to commercial herbicides and these conditions.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that the evidence does not support a causal relationship between his in-service exposure to PCBs and his current condition.

The Board remands the case to obtain an addendum opinion addressing whether the Veteran's prostate cancer is related to in-service exposures to firefighting foam and asbestos.

The appeal of the issue of entitlement to service connection for prostate cancer is dismissed due to the Veteran's death.

The Board granted service connection for diabetes mellitus as secondary to service-connected hypertension and denied a compensable rating for erectile dysfunction, while remanding claims for higher ratings and additional service connections.